Eicosapentaenoic acid in the treatment of schizophrenia and depression: Rationale and preliminary double-blind clinical trial results

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 69, Issue 6, 2003, Pages 477-485

  Peet, Malcolm ^a  

^a Swallownest Court Hospital   (United Kingdom)

Author keywords

Depression; Eicosapentaenoic acid; Polyunsaturated fatty acids; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; ARACHIDONIC ACID; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CHLORPROMAZINE; CLOZAPINE; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; ICOSAPENTAENOIC ACID ETHYL ESTER; NEUROLEPTIC AGENT; NEUROTRANSMITTER; NICOTINIC ACID; OLIVE OIL; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PHOSPHOLIPASE A2; POLYUNSATURATED FATTY ACID; PSYCHOTROPIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

CELL LEVEL; CELL MEMBRANE; CLINICAL TRIAL; CORRELATION ANALYSIS; DEPRESSION; DISEASE EXACERBATION; DRUG EFFICACY; DRUG INTOXICATION; ELECTRORETINOGRAPHY; FLUSHING; HUMAN; LONG TERM CARE; NERVE CELL DIFFERENTIATION; PATHOGENESIS; PRIORITY JOURNAL; RATING SCALE; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

EID: 0344010080     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2003.08.020     Document Type: Article

References (91)

1. A. Khan, S.R. Khan, R.M. Leventhal, W.A. Brown, Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the food and drug administration database, Am. J. Psychiatry 158 (2001) 1449-1454.
2. J. Moncrieff, S. Wessely, R. Hardy, Active placebos versus antidepressants for depression (Cochrane Review), in: The Cochrane Library. Vol. 1, Updated Software, Oxford, 2002.
3. J. Donoghue, T.R. Hylan, Antidepressant use in clinical practice: efficacy v effectiveness, Br. J. Psychiatry 179 (Suppl. 42) (2001) 9-17.
4. H.R. Markar, A.J. Mander, Efficacy of lithium prophylaxis in clinical practice, Br. J. Psychiatry 155 (1989) 496-500.
5. J.D. Hegarty, R.J. Baldessarini, M. Tohen, G. Waternaux, G. Oepen, One hundred years of schizophrenia: a meta-analysis of the outcome literature, Am. J. Psychiatry 151 (1994) 1409-1416.
6. J. Angst, R. Sellaro, Historical perspectives and natural history of bipolar disorder, Biol. Psychiatry 48 (2000) 448-457.
7. S.E. Hyman, E.J. Nestler, Initiatives and adaptation: a paradigm for understanding psychotropic drug action, Am. J. Psychiatry 153 (1996) 151-162.
8. L.D. Seleman, M.S. Lindow, P.S. Goldman-Rakie, Increased volume and glial density in primate prefrontal cortex associates with chronic antipsychotic drug exposure, Biol. Psychiatry 46 (1999) 161-172.
9. P.J. Harrison, The neuropathological effects of antipsychotic drugs, Schizophr. Res. 40 (1999) 87-99.
10. H. Aston, Protracted withdrawal syndromes from benzodiazepines, Abuse Treat. 8 (1991) 19-28.
11. R.J. Baldessarini, L. Tando, G. Floris, N. Rudas, Reduced morbidity after gradual discontinuation of lithium for bipolar disorder: a replication study. Am. J. Psychiatry 154 (1997) 551-553.
12. T.M. Shiovitz, T.L. Welke, P.D. Tigel, et al., Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal, Schizophr. Bull. 22 (1996) 591-595.
13. M. Peet, Induction of mania with selective serotonin reuptake inhibitors and tricyclic antidepressants, Br. J. Psychiatry 164 (1994) 549-550.
14. L.L. Altshuler, R.M. Post, G.S. Leverich, K. Mikalauskas, A. Rosoff, L. Ackerman, Antidepressant-induced mania and cycle acceleration: a controversy revisited. Am. J. Psychiatry 152 (1995) 1130-1138.
15. J. Ballesteros, A. Gonzalez-Pinto, A. Bulbena, Tardive dyskinesia associated with higher mortality in schizophrenic patients: results of a meta-analysis of seven independent studies, J. Clin. Psychopharmacol. 20 (2000) 188-194.
16. J.A. Henry, Epidemiology and relative toxicity of antidepressant drugs in overdose, Drug Saf. 16 (1997) 374-390.
17. P.A. Lipscomb, Cardiovascular side-effects of phenothiazines and tricyclic antidepressants. A review with precautionary measures, Postgrad. Med. J. 67 (1980) 189-192, 195-196.
18. W.A. Ray, S. Meredith, P.B. Thapa, K.G. Meador, K. Hall, K.T. Murray, Anti psychotics and the risk of sudden cardiac death, Arch. Gen. Psychiatry 58 (2001) 1161-1167.
19. R.S. McIntyre, S.M. McCann, S.H. Kennedy, Antipsychotic metabolic effects: weight gain, diabetes, mellitus and lipid abnormalities, Can. J. Psychiatry 46 (2001) 273-281.
20. P.D. La Ferre, Improving the physical health of patients with schizophrenia: therapeutic nihilism or realism?, Scott. Med. J. 46 (2001) 11-13.
21. T.J. Crow, Schizophrenia is the price that homo sapiens pay for language: a resolution of the central paradox in the origin of the species, Brain Res. 31 (2000) 118-129.
22. D.F. Horrobin, Schizophrenia: the illness that made us human, Med. Hypotheses 50 (1998) 269-288.
23. D.F. Horrobin, The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia, Schizophr. Res. 30 (1998) 193-208.
24. J.W. Pettegrew, M.S. Kersharan, K. Panchalingam, et al., Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy, Arch. Gen. Psychiatry 48 (1991) 563-568.
25. H. Fukuzako, T. Fukuzako, T. Hashiguchi, S. Kodama, M. Takigawa, T. Fujimoto, Changes in levels of phosphorus metabolites in temporal lobes of drug naive schizophrenic patients, Am. J. Psychiatry 156 (1999) 1205-1208.
26. J.A. Stanley, P.C. Williamson, D.J. Drost, et al., An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy, Arch. Gen. Psychiatry 52 (1995) 399-406.
27. S. Klemm, R. Rzanny, S. Riehemann, et al., Cerebral phosphate metabolism in first-degree relatives of patients with schizophrenia, Am. J. Psychiatry 158 (2001) 958-960.
28. T. Shioiri, H. Hamakawa, T. Kato, et al., Frontal lobe membrane phospholipid metabolism and ventricle to brain ratio in schizophrenia: preliminary 31P-MRS and CT studies, Eur. Arch. Psychiatry Clin. Neurosci. 250 (2000) 169-174.
29. H. Fukuzako, T. Fukuzako, K. Takeuchi, et al., Phosphorus magnetic resonance spectroscopy in schizophrenia: correlation between member phospholipid metabolism - the temporal lobe and positive symptoms, Prog. Neuropsychopharmacol. Biol. Psychiatry 20 (1996) 629-640.
30. T. Shioiri, T. Someya, J. Murashita, et al., Multiple regression analysis of relationship between frontal lobe phosphorus metabolism and clinical symptoms in patients with schizophrenia, Psychiatry Res. 76 (1997) 113-122.
31. J. Yao, J.A. Stanley, R.D. Reddy, M.S. Keshavan, J.W. Pettegrew, Correlations between peripheral polyunsaturated fatty acid content and in vivo membrane phospholipid abnormalities, Biol. Psychiatry 52 (2002) 823-830.
32. 2 activity in schizophrenia, Schizophr. Res. 16 (1995) 1-6.
33. 2, Arch. Gen. Psychiatry 54 (1997) 487-494.
34. 2 activities in brain of patients with schizophrenia, Brain Res. 821 (1999) 407-413.
35. 2 signalling pathway, Life Sci. 68 (2001) 2885-2891.
36. D.F. Horrobin, Schizophrenia: a biochemical disorder?, Biomedicine 32 (1980) 54-55.
37. P.E. Ward, J. Sutherland, E.M. Glen, A.I. Glen, Niacin skin flush test in schizophrenia: a preliminary report, Schizophr. Res. 29 (1998) 269-274.
38. S. Shah, M. Peet, C.N. Ramchand, Unmedicated patients have a reduced skin flush in response to topical niacin, Schizophr. Res. 43 (2000) 159-166.
39. M.C. Waldo, Co-distribution of sensory gating and impaired niacin flush response in parents of schizophrenics, Schizophr. Res. 40 (1999) 49-53.
40. J.D. Morrow, J.A. Dates, L.J. Roberts, Identification of the skin as a major site of cutaveous vasodilation after oral niacin, Invest. Dermatol. 98 (1992) 812-815.
41. T. Ruzicka, M.P. Printz, Arachidonic acid metabolism in guinea pig skin, Biochem. Biophys. Acta 711 (1982) 391-397.
42. W.W. Eaton, C. Hayward, R. Ram, Schizophrenia and rheumatoid arthritis: a review, Schizophr. Res. 6 (1992) 181-192.
43. M. Peet, J. Laugharne, N. Rangainjan, D. Horrobin, G. Reynolds, Depleted red cell membrane fatty acids in drug treated schizophrenic patients, Psychiatr. Res. 29 (1995) 227-232.
44. A.M. Glen, E.M.T. Glen, D.F. Horrobin, K.S. Vaddadi, M. Spellman, N. Morse-Fisher, et al., A red blood cell membrane abnormality in a sub group of schizophrenic patients: evidence for two diseases, Schizophr. Res. 12 (1994) 53.
45. J. Assies, R. Lieverse, P. Vreken, R.J.A. Wanders, P.M.J.A. Dingemans, D.H. Linszen, Significantly reduced docosahexaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group, Biol. Psychiatry 49 (2001) 510-522.
46. S.P. Mahadik, S. Mukerhee, E. Corrent, H.S. Kelhar, C.G. Wakade, R.M. Costa, et al., Distribution of plasma membrane phospholipids and cholesterol in skin fibroblasts from drug naive patients at the onset of psychosis, Schizophr. Res. 13 (1994) 239-247.
47. J.K. Yao, S. Leonard, R.D. Reddy, Membrane phospholipid abnormalities in post mortem brains from schizophrenic patients, Schizophr. Res. 42 (2000) 7-17.
48. B.G. Jeffrey, H.S. Weisingerb, M. Neuringer, D.C. Mitchell, The roles of docosahexaenoic acid in retinal function, Lipids 36 (2001) 859-871.
49. R. Warner, J. Laugharne, M. Peet, L. Brown, N. Rogers, Retinal function as a marker for cell membrane omega-3 fatty acid depletion in schizophrenia: a pilot study, Biol. Psychiatry 45 (1999) 1138-1142.
50. M.T. Neuringer, W.E.T. Connor, D.S. Lin, L. Barstad, S. Luck, Biochemical and functional effects of prenatal and postnatal omega-3 fatty acid deficiency on retina and brain in rhesus monkeys, Proc. Natl. Acad. Sci. USA 83 (1986) 4021-4025.
51. O. Christensen, E. Christensen, Fat consumption and schizophrenia, Acta Psychiatr. Scand. 78 (1988) 587-591.
52. J.E. Mellor, J.D.E. Laugharne, M. Peet, Omega-3 fatty acid supplementation in schizophrenia patients, Hum. Psychopharmacol. 11 (1996) 39-46.
53. A. Malnae, H. Milan, C. Revue, Effect of in vivo modulation of membrane docosahexaenoic acid levels on the dopamine-dependant adenylate cyclase activity in rat retina, J. Neurochem. 55 (1990) 1480-1485.
54. M.R. Witt, M. Nielsen, Characterisation of the influence of unsaturated free fatty acids on brain GABA/benzodiazepine receptor binding in vitro, J. Neurochem. 62 (1994) 1432-1439.
55. C.J. Hudson, T. Young, J.J. Lipp, Warsh, CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia, Synapse 13 (1993) 278-293.
56. A.A. Farooqui, L.A. Horrocks, T. Farooqui, Glycerophospholipids in brain: their metabolism, incorporation into membranes and involvement in neurological disorders, Chem. Phys. Lipids 106 (2000) 1-29.
57. L.S. Pilowsky, R.W. Kerwin, R.M. Murray, Schizophrenia: a neurodevelopmental perspective, Neuropsychopharmacology 9 (1993) 83-91.
58. R. Uauy, D.R. Hoffman, P. Peirano, D.G. Birch, E.E. Birch, Essential fatty acids in visual and brain development, Lipids 36 (2001) 885-895.
59. G.L. Klerman, M.M. Weissman, Increasing rates of depression, JAMA 261 (1989) 2229-2235.
60. A. Doris, K. Ebmeier, P. Shajahan, Depressive illness, Lancet 354 (1999) 1369-1375.
61. J. Hibbeln, N. Salem, Dietary polyunsaturated fatty acids and depression: when cholesterol does not satisfy, Am. J. Clin. Nutr. 62 (1995) 1-9.
62. J. Hibbeln, Fish consumption and major depression, Lancet 351 (1998) 1213.
63. J. Hibbeln, Long-chain polyunsaturated fatty acids in depression and related conditions, in: M. Peet. I. Glen, D. Horrobin (Eds.), Phospholipid Disorder in Psychiatry, Marius Press, Carnforth, UK, pp. 195-210.
64. A. Taskanen, J.R. Hibbeln, J. Tuomilehto, et al., Fish consumption and depressive symptoms in the general population in Finland, 52 (2001) 529-531
65. R. Edwards, M. Peet, J. Shay, D. Horrobin, Omega-3 polyunsaturated fatty acid levels in the diet and red blood cell membranes of depressed patients, J. Affect. Disord. 48 (1998) 149-155.
66. M. Maes, R. Smith, A. Christophe, P. Cosyns, R. Desnyder, H. Meltzer, Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20:4 omeqa6/20:5 omega 3 ratio in cholesteryl esters, J. Affect. Disord. 38 (1996) 35-46.
67. M. Peet, B. Murphy, J. Shay, D. Horrobin, Depletion of omega-3 fatty acids levels in red blood cell membranes of depressive patients, Biol. Psychiatry 43 (1998) 315-319.
68. P.B. Adams, S. Lawson, A. Sanigorski. A.J. Sinclair, Arachidonic acid to eicosapentaenoic acid ratio in red blood cells correlates positively with clinical symptoms of depression, Lipids 31 (Suppl.) (1996) S157-S161.
69. C.R. Harper, T.A. Jacobson, The fats of life: the role of omega-3 fatty acids in the prevention of coronary heart disease, Arch. Intern. Med. 161 (2001) 2185-2192.
70. B.W. Penninx, A.T. Beeknan, A. Honig, et al., Depression and cardiac mortality: results from a community-based study, Arch. Gen. Psychiatry 58 (2001) 221-227.
71. E.S. Ford, W.H. Giles, W.H. Dietz, Prevalence of the metabolic syndrome among US adults: findings from the third national health and nutrition examination survey, JAMA 287 (2002) 356-359.
72. W.W. Eaton, H. Armenian, J. Gallo, L. Pratt, D.E. Ford, Depression and risk for onset of type II diabetes. A prospective population based study, Diabetes Care 19 (1996) 1097-1102.
73. K. Davidson, B.S. Jonas, K.E. Dixon, J.H. Markovitz, Do depressive symptoms predict early hypertension incidence in young adults in the CARDIA study? Coronary artery risk development in young adults, Arch. Intern. Med. 160 (2000) 1495-1500.
74. R.G. McCreadie, R. Thara, S. Kamoth, et al., Abnormal movements in never-medicated Indian patients with schizophrenia, Br. J. Psychiatry 168 (1996) 221-226.
75. M. Peet, J. Brind, C.N. Ramchand, S. Shah, G.K. Vankar, Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia, Schizophr. Res. 49 (2001) 243-251.
76. M. Peet, D.F. Horrobin. A dose-ranging exploratory study of the effects of ethyl eicosapentaenoate in patients with persistent schizophrenic symptoms, J. Psychiatr. Res. 36 (2002) 7-18.
77. W.S. Fenton, F. Dickerson, J. Boronow, J.R. Hibbeln, M. Knable, A placebo-controlled trial of omega-3 fatty acid (ethyl eiscosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia, Am. J. Psychiatry 158 (2001) 2017-2074.
78. B.K. Puri, A.J. Richardson, D.F. Horrobin, et al., Eicosapentaenoic acid treatment in schizophrenia associated with symptom remission, normalisation of blood fatty acids, reduced neuronal membrane phospholipid turnover and structural brain changes, Int. J. Clin. Pract. 54 (2000) 57-63.
79. K.P. Su, W.W. Shen, S.Y. Huang, Omega 3 fatty acids as a psychotherapeutic agent for a pregnant schizophrenic patient, Eur. Neuropsychopharmacol. 11 (2001) 205-209.
80. L.B. Marangell, H.A. Zboyan, K.K. Cress, et al., A double-blind, placebo-controlled study of docosahexaenoic acid in the treatment of depression, Inform 11 (2000) 578.
81. M. Peet, D.F. Horrobin, A dose-ranging study of the effects of ethyl eicosapentaenoate in patients with ongoing depression in spite of apparently adequate treatment with standard drugs, Arch. Gen. Psychiatry 59 (2002) 913-919.
82. R.A. Emsley, C.C. Myburgh, P.P. Oosthuizen, S.J. Van Rensburgh, Randomised placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia, Am. J. Psychiatry 159 (2002) 1596-1598.
83. B. Nemets, Z. Stalil, R.H. Belmaker, Addition of Omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder, Am. J. Psychiatry 59 (2002) 477-479.
84. B.K. Puri, S.J. Counsell, G. Hamilton, A.J. Richardson, Horrobin D.F. Eicosapentaenoic acid in treatment-resistant depression associated with symptom remission, structural brain changes and reduced phospholipid turnover, Int. J. Clin. Pract. 55 (2001) 560-563.
85. A.L. Stoll, W.E. Severus, M.P. Freeman, et al., Omega-3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial, Arch. Gen. Psychiatry 56 (1999) 407-412.
86. M. Peet, J.D. Laugharne, D.F. Horrobin, G.P. Reynolds, Arachidonic acid: a common link in the biology of schizophrenia?, Arch. Gen. Psychiatry 51 (1994) 665-666.
87. M. Peet, J.D.E. Laugharne, N. Ahluwalia, J. Melior, Fatty acid supplementation in schizophrenic patients, presented at International Congress on Schizophrenia Research, Colorado Springs USA, Schizophr. Res. 24 (1,2) (1997) 255.
88. E.A. Thomas, P.E. Danielson, P.A. Nelson, et al., Clozapine increases alipoprotein D expression in rodent brain: towards a mechanism for neuroleptic pharmacotherapy, J. Neurochem. 76 (2001) 789-796.
89. E.A. Thomas, B. Dean, G. Pavey, J.G. Suttcliffe, Increased CNS levels of alipoprotein D in schizophrenic and bipolar patients: implications for the pathophysiology of psychiatric disorders, Proc. Natl. Acad. Sci. USA 98 (2001) 4066-4071.
90. S.P. Mahadik, M.M. Khan, D.R. Evans, V.V. Parikh, Elevated plasma level of apolipoprotien D in schizophrenia and its treatment and outcome, Schizophr. Res. 58 (2002) 55-62.
91. J.H. Morais Cabrai, G.L. Atkins, L.M. Sanchez, V.S. Lopez-Boado, L. Sawyer, Arachiconic acid binds to alipoprotein D: implications for the protein's function, FEBS Lett. 366 (1995) 53-56.